Xenetic Biosciences (XBIO) EBT (2011 - 2026)

Xenetic Biosciences (XBIO) has reported EBT for 16 consecutive years, with -$929623.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 34.69% year-over-year to -$929623.0; the trailing twelve-month figure through Jun 2026 stood at -$2.6 million (up 20.0% YoY), and the FY2025 full-year result was -$2.8 million, up 32.58% from the prior year.
• EBT retreated to -$929623.0 in Q2 2026 per XBIO's latest filing, from -$456361.0 in the prior quarter.
• Across five years, EBT topped out at -$456361.0 in Q1 2026 and bottomed at -$2.7 million in Q2 2022.
• Historically, EBT has averaged -$1.1 million across 5 years, with a median of -$1.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: EBT tumbled 138.29% in 2022, then surged 56.44% in 2024.
• Over 5 years, EBT stood at -$1.6 million in 2022, then grew by 19.68% to -$1.3 million in 2023, then advanced by 12.47% to -$1.1 million in 2024, then jumped by 43.32% to -$623027.0 in 2025, then tumbled by 49.21% to -$929623.0 in 2026.
• According to Business Quant data, EBT over the past three periods registered -$929623.0, -$456361.0, and -$623027.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.